Structure Therapeutics Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)



· · · YEAR ENDED DECEMBER 31,
· · · 2025 · · 2024 · · 2023
Operating expenses:
Research and development	$225,255	$108,814	$70,103
General and administrative	61,554	49,414	32,672
Other license income	(100,000)	—	—
Gains on sale of non-financial assets	(10,249)	—	—
Total operating expenses	176,560	158,228	102,775
Loss from operations	(176,560)	(158,228)	(102,775)
Interest and other income, net	35,873	36,012	13,391
Loss before provision for income taxes	(140,687)	(122,216)	(89,384)
Provision for income taxes	515	310	236
Net loss attributable to ordinary shareholders	$(141,202)	$(122,526)	$(89,620)
Net loss per share attributable to ordinary shareholders, basic and diluted	$(0.80)	$(0.78)	$(0.81)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted	177,596	157,922	110,198
Other comprehensive income:
Unrealized gain on investments, net	140	393	631
Total other comprehensive income	140	393	631
Comprehensive loss	$(141,062)	$(122,133)	$(88,989)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.